Vertex to Cease Clinical Trials on Diabetes Treatment
Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.
Vertex Pharmaceuticals pursuing research-stage T1Dd programs
Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...
Vertex Pharmaceuticals says VX-264 study did not meet primary endpoint
Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...
The Motley Fool19d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
GitHub23d
Small and simple software for plotting data from serial port in realtime.
See hackaday.io page for screenshots. Qwt is the library that provides plotting widgets for SerialPlot. You have 3 different options for Qwt. Leave it to serialplot ...
BioPharma Dive25d
Vertex’s new pain drug gets first coverage nod from major insurer
Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...